share_log

Intelligent Bio Solutions | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lind Global Fund II LP(9.9%),Lind Global Partners II LLC(9.9%), etc.

Intelligent Bio Solutions | SC 13G/A:超过5%持股股东披露文件(修正)-Lind Global Fund II LP(9.9%),Lind Global Partners II LLC(9.9%)等

美股sec公告 ·  02/13 20:12
Moomoo AI 已提取核心信息
On December 31, 2023, a Schedule 13G amendment was filed with the SEC by Intelligent Bio Solutions Inc., indicating a significant ownership stake by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton. The filing, which is a regulatory requirement for parties owning more than five percent of a company's stock, shows that these entities and individual collectively hold 960,000 shares of Intelligent Bio Solutions' common stock, representing 9.9% of the company. The ownership consists of warrants to purchase common stock, but due to exercise limitations, the beneficial ownership is capped at 960,000 shares. Jeff Easton, as the managing member of Lind Global Partners II LLC and the general partner of Lind Global Fund II LP, is deemed to have sole voting and dispositive power over the shares held by Lind Global Fund II LP. The principal business office for all reporting persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, includes a joint filing agreement among the reporting persons.
On December 31, 2023, a Schedule 13G amendment was filed with the SEC by Intelligent Bio Solutions Inc., indicating a significant ownership stake by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton. The filing, which is a regulatory requirement for parties owning more than five percent of a company's stock, shows that these entities and individual collectively hold 960,000 shares of Intelligent Bio Solutions' common stock, representing 9.9% of the company. The ownership consists of warrants to purchase common stock, but due to exercise limitations, the beneficial ownership is capped at 960,000 shares. Jeff Easton, as the managing member of Lind Global Partners II LLC and the general partner of Lind Global Fund II LP, is deemed to have sole voting and dispositive power over the shares held by Lind Global Fund II LP. The principal business office for all reporting persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, includes a joint filing agreement among the reporting persons.
2023年12月31日,Intelligent Bio Solutions Inc. 向美国证券交易委员会提交了附表13G修正案,表明Lind Global Fund II LP、Lind Global Partners II LLC和Jeff Easton拥有大量所有权。该文件是监管部门对拥有公司5%以上股票的各方的要求,显示这些实体和个人共持有Intelligent Bio Solutions普通股的96万股,占该公司的9.9%。所有权包括购买普通股的认股权证,但由于行使限制,受益所有权上限为960,000股。杰夫·伊斯顿作为Lind Global Partners II LLC的管理成员...展开全部
2023年12月31日,Intelligent Bio Solutions Inc. 向美国证券交易委员会提交了附表13G修正案,表明Lind Global Fund II LP、Lind Global Partners II LLC和Jeff Easton拥有大量所有权。该文件是监管部门对拥有公司5%以上股票的各方的要求,显示这些实体和个人共持有Intelligent Bio Solutions普通股的96万股,占该公司的9.9%。所有权包括购买普通股的认股权证,但由于行使限制,受益所有权上限为960,000股。杰夫·伊斯顿作为Lind Global Partners II LLC的管理成员和Lind Global Fund II LP的普通合伙人,被视为对Lind Global Fund II LP持有的股票拥有唯一的投票权和处置权。所有申报人的主要业务办公室位于纽约麦迪逊大道444号41楼,邮编10022。该文件日期为2024年2月13日,包括申报人之间的联合申报协议。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息